No current positioning snapshot.
Current snapshotPublic companyResearch currentFresh
COMMUNITY HEALTH SYSTEMS INC
Intervene · Healthspan Infrastructure
SignalWATCHReviewed 25 Oct 2026
Intervene exposure in Healthspan Infrastructure.
Community Health Systems operates acute-care hospitals and is a buyer of imaging capital equipment
Catalysts
Q3 2026 results 10-28-26 after close, call 10-29-26 (company PR 10-14-26). Q2 2026 net operating revenue $2,825M with net income $104M (8-K 2.02/7.01 07-22-26). Balance-sheet deleveraging remains the swing factor at 1.5x PE / ~$385M cap.
Invalidation
needs primary source validation — pending deep-dive research. Placeholder: (1) thesis chain breaks on primary-source evidence, (2) named revenue/customer concentration risk, (3) margin compression or competitive displacement
Latest change
· Coverage moved from — to Added to coverage.
Capital in context
Mapped funds and investors
Direct relationships supported by published evidence.
Reported holdings as-of
No sourced relationships mapped yet.
Disclosed investment history
No sourced relationships mapped yet.
Showing up to four relationships in each group. ETF weights describe the fund’s portfolio, not ownership of this company. Private investment history does not establish current ownership.
needs primary source validation — no X/Reddit signal yet
Lower-confidence snapshotTarget price: $2.96
Dated research targetMoat & position
- Evidence Grade
- Inferred
- Toll Road Tier
- BODY_SHOP
2026-10-28 · earnings
Timestamped research update
Deep research update
1,051 words · Updated 22 Oct 2026 · 5 sources
COMMUNITY HEALTH SYSTEMS INC (None, CIK 0001108109) — US-listed company materially exposed to Medical Imaging Systems.
Community Health Systems, Inc. (“CYH”) is one of the largest publicly traded hospital operators in the United States, with a portfolio concentrated in non-urban and suburban markets. The company’s FY2023 Form 10-K describes a single reportable segment: hospital operations. CYH owns, leases, or operates general acute care hospitals, outpatient surgery centers, physician clinics, urgent care centers, and related ambulatory services. The company does not report separate business segments; the hospital operations segment is effectively 100% of consolidated revenue.
CYH’s customers are patients, but its payers are the economic buyers. The buyer archetypes disclosed or clearly identifiable from the filing are:
- Medicare beneficiaries — patients over 65 or with qualifying disability/end-stage conditions. Medicare is the most important federal payer.
- Medicaid beneficiaries — lower-income patients, including those covered by state Medicaid managed-care plans. CYH’s higher Medicaid exposure relative to HCA is a key difference.
- Commercially insured patients — employer-sponsored health plan members covered through managed care contracts.
- Self-pay/uninsured patients — patients with no insurance or high-deductible exposure; the 10-K treats this as a distinct revenue category with higher collection risk.
The 10-K names Medicare and Medicaid as material government payer programs. It does not provide a single named private insurer with revenue concentration, so no named commercial customer is cited here. If management disclosed material concentration, it would appear in the risk factors or revenue recognition disclosure; the absence of such disclosure means no private payer is individually load-bearing for revenue.
Community Health Systems operates acute-care hospitals and is a buyer of imaging capital equipment
- Community Health Systems operates acute-care hospitals and is a buyer of imaging capital equipment source
- COMMUNITY HEALTH SYSTEMS INC — SEC EDGAR company filings source
| Parameter | Value | Source | Tier | Measured/derived/assumed | Cross-verified |
|---|---|---|---|---|---|
| Net operating revenues FY2023 | $12,493M | CYH 10-K, acc. 0001108109-24-000007, 2024-02-21 | Tier 1 | Measured | Single-source |
| Net loss attributable to CYH FY2023 | $(133)M | CYH 10-K, same | Tier 1 | Measured | Single-source |
| Adjusted EBITDA FY2023 | $1,374M | CYH 10-K, same | Tier 1 | Measured/derived non-GAAP | Single-source |
| Long-term debt | $11,501M | CYH 10-K, same | Tier 1 | Measured | Single-source |
| Cash | $1,046M | CYH 10-K, same | Tier 1 | Measured | Single-source |
| Interest expense | $835M | CYH 10-K, same | Tier 1 | Measured | Single-source |
| Hospital count | 76 | CYH 10-K, same | Tier 1 | Measured | Single-source |
| States | 15 | CYH 10-K, same | Tier 1 | Measured | Single-source |
| Payer mix: Medicare | ~23% | CYH 10-K, same | Tier 1 | Measured; decimal needs validation | Single-source |
| Payer mix: Medicaid | ~16% | CYH 10-K, same | Tier 1 | Measured; decimal needs validation | Single-source |
| Payer mix: managed care/other | ~55% | CYH 10-K, same | Tier 1 | Measured; decimal needs validation | Single-source |
| Payer mix: self-pay | ~5% | CYH 10-K, same | Tier 1 | Measured; decimal needs validation | Single-source |
| Revenue per hospital | $164.4M | Derived from CYH 10-K revenue/hospital count | Tier 1 | Derived | Single-source |
| Adjusted EBITDA per hospital | $18.1M | Derived from CYH 10-K EBITDA/hospital count | Tier 1 | Derived | Single-source |
| Net leverage | 7.61x | Derived from CYH 10-K | Tier 1 | Derived | Single-source |
| Interest coverage | 1.65x | Derived from CYH 10-K | Tier 1 | Derived | Single-source |
| HCA net operating revenues FY2023 | $64,968M | HCA 10-K, acc. 0000860730-24-000006, 2024-02-16 | Tier 1 | Measured | Single-source |
| HCA operating income FY2023 | $9,607M | HCA 10-K, same | Tier 1 | Measured | Single-source |
| HCA net income attributable FY2023 | $5,242M | HCA 10-K, same | Tier 1 | Measured | Single-source |
| HCA hospital count | 186 | HCA 10-K, same | Tier 1 | Measured | Single-source |
_Pending primary-source company deep-dive._
CYH sells acute and post-acute healthcare services. The product is the operation of licensed hospitals and affiliated outpatient sites that provide:
- Emergency care
- Inpatient general surgery and specialty surgery
- Intensive care and cardiac care
- Obstetrics and neonatal care
- Orthopedic and spine care
- Diagnostic imaging and laboratory services
- Outpatient surgery
- Urgent care and telehealth
- Physician clinic services
The 10-K describes the company as operating general acute care hospitals, many in communities where the CYH hospital may be the only full-service acute-care facility in the local market. That local-market characteristic is central to the product story.
CYH has limited ability to raise prices on government payers because Medicare and Medicaid set administratively. The company can negotiate commercial rates, but those negotiations are constrained by insurer concentration and employer pressure to reduce cost. CYH’s pricing power is therefore strongest in markets where it is the only acute-care hospital and where commercial payers need network access. The 10-K risk factors describe reimbursement pressure from government programs and managed-care payers as an ongoing risk, which supports the conclusion that pricing power is limited.
_Pending primary-source company deep-dive._
The investment/operating thesis on CYH would be invalidated or materially weakened by any of the following:
- Same-store volume declines. If same-facility admissions and adjusted admissions decline while labor and supply costs remain sticky, adjusted EBITDA would fall and leverage would worsen. The current interest coverage of only 1.65x leaves very little buffer.
- Payer mix shifts further toward government reimbursement. If commercial/managed-care volumes shrink and Medicare/Medicaid become an even larger share of revenue, revenue per adjusted admission would decline. CYH already discloses a material government-payer mix, so further mix shift would compress margin.
- Divestitures remove EBITDA but not overhead. If CYH continues selling hospitals but corporate and interest expense remain high, the EBITDA-per-hospital calculation may improve optically while net leverage worsens. A portfolio shrink alone does not fix the balance sheet.
- Wage inflation outpaces reimbursement. Hospital wage inflation, especially for nurses and specialized staff, could expand salary expense faster than commercial or government rate increases. The 10-K identifies labor costs as a risk; a multi-year wage spiral would negate pricing gains.
- Commercial rate resets lower. If payers successfully renegotiate multi-year contracts at lower rates or steer volume to ambulatory surgery centers and telehealth, CYH’s residual pricing power would erode.
- Interest rates or refinancing stress. With net leverage above 7.5x and interest coverage below 2x, a credit-rating downgrade or adverse refinancing environment could force asset sales at unfavorable prices or restrict liquidity.
The thesis fails most clearly if the company cannot convert positive Adjusted EBITDA into sustained GAAP net income and free cash flow while reducing debt.
INTACT (exposure surfaced from technology map; no capital allocation)
Primary and supporting material
Sources
5 sources preserved from the latest qualified research update.